CORRECTION, 5/29/13, 6:55 p.m. EDT: The names of Osler partner Peter Glossop and associate Amanda Heale were misspelled in the original version of this article. The names have been corrected in the tenth paragraph. We regret the error.
After months of eyeing possible acquisition targets, Canada’s Valeant Pharmaceuticals International decided to narrow its sights on Bausch & Lomb.
Laval, Quebecbased Valeant said Monday that it has agreed to acquire the contact lens maker in a cash deal worth $8.7 billion. The transaction’s terms call for Valeant to pay $4.5 billion to a group of Bausch & Lomb investors led by private equity firm Warburg Pincus, with the remaining $4.2 billion earmarked to pay off the target’s debt.
